Linkedin

Press and media

Press releases

More regular updates and key information, updates and news can be found through our tweets

Follow us on LinkedIn

CellCentric expands executive team with new Chief Development Officer

4 September 2024 Press Release

CellCentric Secures $35 Million Investment from RA Capital Management

24 July 2024 Press Release

CellCentric discloses significant new clinical data, demonstrating inobrodib’s efficacy in ongoing Phase I/IIa clinical trials

11 December 2023 Press Release

Inobrodib’s novel mechanism: new data published in Cancer Cell

22 November 2023 Press Release

CellCentric secures further investment from BrightEdge, the American Cancer Society’s impact investment and innovation arm

12 September 2023 Press Release

CellCentric announces $25m strategic investment from Pfizer

11 July 2023 Press Release

CellCentric Granted FDA Orphan Drug Designation for Inobrodib (CCS1477) for the Treatment of Multiple Myeloma

29 June 2023 Press Release

CellCentric receives FDA Fast Track designation for inobrodib for the treatment of patients with relapsed refractory multiple myeloma

13 June 2023 Press Release

CellCentric presents early haem clinical data at ASH

11 December 2022 Press Release

CellCentric to present haem clinical data at ASH

4 November 2022 Press Release

CellCentric strengthens leadership team

6 April 2022 Press Release

CellCentric secures investment from the American Cancer Society’s impact venture capital fund

26 January 2022 Press Release

Inobrodib

A first-in-class oral
anti-cancer drug

Find out more

Latest tweets from @CellCentric

Follow us on Twitter
Main Menu
Follow us on LinkedIn